NCT01939327View on ClinicalTrials.gov

Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

October 31, 2017

Study Completion Date

January 31, 2020

Conditions
Non-Hodgkin Lymphoma
Interventions
DRUG

Lenalidomide/Rituximab

Trial Locations (1)

13009

Institut Paoli-Calmettes, Marseille

All Listed Sponsors
lead

Institut Paoli-Calmettes

OTHER

NCT01939327 - Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter